PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34697111-1 2021 INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen (HBsAg) levels to achieve functional cure and improve long-term prognosis in chronic hepatitis B patients. pegylated interferon alpha 79-105 interferon alpha 1 Homo sapiens 111-120 32885325-2 2020 The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. pegylated interferon alpha 55-81 interferon alpha 1 Homo sapiens 83-91 32885325-2 2020 The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. pegylated interferon alpha 55-81 interferon alpha 1 Homo sapiens 106-117 32100261-1 2020 BACKGROUND: As an important anti-HBV drug, pegylated interferon alpha (PegIFNalpha) offers promising clinical efficacy, but biomarkers that accurately forecast treatment responses are yet to be elucidated. pegylated interferon alpha 43-69 interferon alpha 1 Homo sapiens 71-82